Details of the Drug Combinations

General Information of This Drug (ID: DMX7V28)

Drug Name

Insulin-aspart DMX7V28

Synonyms

Aspart; NovoLog; NovoRapid; Aspart insulin; Insulin aspart; Insulin aspart [USAN]; Insulin X14; NovoMix 30; NovoRapid 30 Mix; INA-X 14; Novolog mix 70/30; AspB28-insulin (human); B28-Asp-insulin; (AspB28)-human insulin; 28(sup B)-L-Aspartic acid-insulin (human)

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Hypoglycemic Agents

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Liraglutide + Insulin-aspart	DC4P2O4	Liraglutide	Diabetes Mellitus, Type II	[2]
Insulin-glargine + Insulin-aspart	DC3WH4E	Insulin-glargine	Type 2 Diabetes	[3]
Insulin-glargine + Insulin-aspart	DCD9TWJ	Insulin-glargine	Hyperglycemia Steroid-induced	[4]
------------------------------------------------------------------------------------

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	ClinicalTrials.gov (NCT01654120) Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
3	ClinicalTrials.gov (NCT03336528) Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
4	ClinicalTrials.gov (NCT03511521) Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia